The efficacy of contrast protocol in hepatic dynamic computed tomography: multicenter prospective study in community hospitals by Masahiro Okada et al.
a SpringerOpen Journal
Okada et al. SpringerPlus 2013, 2:367
http://www.springerplus.com/content/2/1/367RESEARCH Open AccessThe efficacy of contrast protocol in hepatic
dynamic computed tomography: multicenter
prospective study in community hospitals
Masahiro Okada1*, Hiroshi Kondo2, Hironobu Sou3, Takamichi Murakami1, Masayuki Kanematsu2,
Tomoaki Ichikawa3, Shushi Yoshikawa4, Kazuhito Shiosakai5, Akiko Hayakawa6, Kazuo Awai7,
Kengo Yoshimitsu8 and Yasuyuki Yamashita9Abstract
Purpose: To investigate four different contrast protocols to detect hypervascular hepatocellular carcinoma (HCC)
most adaptable for patients at any body weight (BW) in clinical practice.
Materials and methods: A post-marketing surveillance of liver dynamic CT was prospectively performed by four
different protocols in 415 patients: Protocol-A, BW-tailored dose of contrast media (CM: iohexol 300 mgI/mL), fixed
injection duration (30s), fixed scan timing at arterial phase (AP); Protocol-B, BW-tailored dose of CM, fixed injection
duration (30s), by bolus tracking; Protocol-C, BW-tailored dose of CM, fixed injection flow rate, by bolus tracking;
Protocol-D, 100 mL constant of CM at any BW, fixed scan timing. Scan timing and tumor conspicuity at AP was
scored qualitatively. The quantitative CT values of aorta and tumor liver contrast (TLC) were obtained.
Results: The qualitative rate assessed “good” as scan timing of AP in Protocol-C was significantly lower than
those in Protocols A and D (difference:16.6%, 17.4%, P = 0.0069, P = 0.0140, respectively). Scatter plot of Protocol-D
(R2 = 0.1283) at AP showed significant inverse relationship between TLC and BW (P =0.0053), although not
significant in Protocols A, B, C.
Conclusion: In patients with higher BW, protocols of BW-tailored dose of CM and/or fixed injection duration have
no dependence on BW to diagnose hypervascular HCCs.
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Multidetector-row computed tomography (MDCT) has
allowed imaging of the liver in detail, because of the
improved spatial and temporal resolution. But the optimal
techniques for intravenous (IV) injection of contrast media
(CM) and scanning of the liver to diagnose hepatocellular
carcinoma (HCC) have been a subject of controversy for
several years.
HCC is one of the most common malignancies world-
wide. The majority of HCCs develop in cirrhotic livers, thus
the early detection and characterization of this entity is
important for decisions on therapeutic strategy. But, rapid* Correspondence: mokada@gaia.eonet.ne.jp
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in any medium, provided the original work is pscan speed with a MDCT scanner increases the difficulty
to image hypervascular HCC during the arterial phase
(AP) after CM injection. Therefore, we should know
the optimal scanning protocol to start in the AP after
IV injection of CM.
There are several important technical factors for the
injection of CM, such as the dose (i.e. volume and
concentration), injection rate, injection duration, body
weight (BW) and scan delay time in the AP. The volume
of CM, the concentration and the injection rate are directly
related to maximum liver enhancement (Dean et al. 1980;
Berland & Lee 1988; Claussen et al. 1984; Yagyu et al. 2005),
whereas patients’ BWs are inversely related (Kormano et al.
1983). Some investigators have suggested that a minimum
enhancement of 50 Hounsfield Units (HU) is necessary as
adequate liver enhancement to obtain high conspicuity ofn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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1995; Heiken et al. 1995). The total dose of CM is one of
the most important technical factors to determine the
amplitude of the contrast enhancement of the liver,
because a fixed dose of CM provides different effects
in patients with various BWs. Whereas, when we use
the same fractional/total dose of iodine for the depiction of
hypervascular HCC, rapid injection of CM with moderate
concentration is more effective than is high concentration
of CM (Awai et al. 2004a; Han et al. 2000). These facts are
also shown using the theoretical compartmental model of
(Bae et al. 1998a; Bae et al. 1998b) and the observations of
(Awai et al. 2004b; Awai & Hori 2003). The concentration
and injection rate of CM are important for determining
the amplitude of contrast enhancement in hypervascular
HCCs during AP. Moreover, the injection duration is also
important to predict peak enhancement time in the liver,
because it may be the only factor to restrict temporal
changes in contrast enhancement. When a tailored dose of
CM according to patients’ BW is used, a fixed injection
duration method allows the minimization of the variation
in aortic peak enhancement time for each patient
(Ichikawa et al. 2006; Erturk et al. 2008). To achieve
adequate liver enhancement for all patients with a
wide variety of BW on CT, recent clinical studies have
suggested that the dose of CM should be tailored according
to patients’ BWs to obtain adequate liver enhancement
(Awai et al. 2004b; Awai & Hori 2003; Kondo et al. 2008).
The variation in liver enhancement among patients with
different BWs is cancelled by using the BW-tailored dose of
CM (Awai et al. 2004b). Thus, a tailored dose of CM
according to patients’ BW has been a recent trend in
hepatic dynamic CT protocols.
On the other hand, to achieve optimal detection of
hypervascular HCC during the AP in liver dynamic CT,
it is important to predict the peak time of aortic
enhancement, because blood is supplied to tumors from
the hepatic artery (which is a branch of the abdominal
aorta) in patients with hypervascular HCC. The routine
use of computer-assisted bolus tracking techniques
(i.e. SmartPrepW) for AP scanning is recommended to
detect hypervascular HCC (Tomemori et al. 2001).
The imaging by bolus tracking technique is useful to
catch the optimal scan timing during AP in patients
with severe cardiac dysfunction.
Although these fingings above, the fixed injection rate
of CM has been used in dynamic CT protocols of the
liver rather than the fixed injection duration. Moreover,
some radiologists use a uniform dose of intravenous CM
in patients undergoing hepatic dynamic CT, although
experimental data have indicated an inverse relationship
between hepatic contrast enhancement on CT and patient
BW (Kormano et al. 1983). These may be still the actual
situations in some hospitals even nowadays in Japan.Moreover, the condition of the bolus tracking system
settings for rapid scan speed with a MDCT scanner
had not been standardized and optimized in community
hospitals in Japan, although bolus tracking techniques were
introduced into the daily clinical settings in community
hospitals.
To our knowledge, no prospective study has systematic-
ally evaluated the role of CM injection protocols, including
the dose (i.e. volume and concentration), injection
rate, injection duration of CM, BW and scan delay
time in the AP for hepatic dynamic CT for daily clinical
settings in community hospitals.
Therefore, the aim of this study was to investigate
most adaptable protocol for patients at any BW among
the four injection protocols routinely used in community
hospitals in Japan, by focusing the imaging of AP, which
is thought to be the most important for liver dynamic
CT to detect HCC.
Materials and methods
Patients
Since this study was non-interventional study conducted
as post-marketing surveillance in Japan, in which the
data is collected from daily clinical settings in each
hospitals, the hospitals using either one of the following
4 injection protocols routinely used in Japan shown in
the “Imaging methods” section were selected and signed
contract with each hospital for participation in the study.
During the period between June 2010 and November
2010, the study of liver dynamic CT was conducted by
Daiichi Sankyo Co., Ltd., in accordance with the Good
Post-marketing Study Practice (MHLW Ordinance No.
171 issued on December 20, 2004) in the 91 community
hospitals in Japan. After receipt of signed contract
for participation in the study from the 91 hospitals,
consecutive patients who fulfilled the following inclusion
criteria but no exclusion criteria were enrolled under the
conditions of the daily clinical setting, until the target
number of patients was reached. Liver dynamic CT was
performed for 419 patients registered in each hospital, and
all patients received one of 4 injection protocols shown in
the “Imaging methods” section. The inclusion criteria were:
(a) type B or C hepatitis or liver cirrhosis; (b) known HCC
(up to 3 cm in size) without any treatment after the
diagnosis from tumor biopsy, CT during arterial
portography (CTAP) and CT during hepatic arteriography
(CTHA), lipiodol CT, contrast enhanced magnetic reson-
ance imaging with such as gadodiamide (OmniscanW,
Daiichi Sankyo Co., Ltd. Tokyo, Japan), or gadoxetic acid
(PrimovistW; Bayer HealthCare Pharmaceuticals, Berlin,
Germany), contrast enhanced sonography; (c) alternatively,
patients in whom enlargement of tumor or increased
markers for liver cancer alpha-fetoprotein and protein in-
duced by vitamin-K absence II was observed; (d) patients
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underwent liver dynamic CT with 16 detectors-rows or 64
detectors-rows of MDCT for the assessment of HCC.
The exclusion criteria were: (a) patients with hypersen-
sitivity to iodine CM; (b) patients with severe thyroid
diseases; (c) patients with severe renal dysfunction; (d)
patients with metastatic liver diseases; (e) patients
with therapeutic conditions, such as radiofrequency
ablation (RFA) or transarterial chemo-embolization
(TACE) - within 3 months before CT examination;
and (f ) patients with severe fatty liver diseases, who
had higher density of intrahepatic vessels compared
to liver parenchyma on unenhanced CT.
Four of 419 patients were excluded because of the
following reason: two patients were with severe fatty
liver judged by three reviewers of qualitative analysis
as the exclusion criteria of this study, one patient was
not administered iohexol but other iodine component
that differ from the structured study protocol, and
one patient was found to have been enrolled outside
the contract period. Thus final study population
consisted of 415 patients. Subjects’ characteristics are
shown in Table 1. The background, characteristics
and diagnosis methods of HCC are shown in Table 2.
Of 415 patients, 340 had hypervascular HCC and
remaining 75 had hypovascular HCC. These were
from 1–3 HCCs in 318 patients, 4–6 HCCs in 35 patients,
7–9 HCCs in 14 patients and more than 10 HCCs in 48
patients. No obvious imbalance in gender, age and body
weight was observed between the four protocols. There
was no significant difference in weight distribution
between each group of the four protocols (Figure 1).
Imaging methods
Dynamic CT protocols in this study were selected by the
daily work of each hospital. Four injection protocols
were employed for the study as follows: Protocol-A,
BW-tailored dose of CM (300 mgI/mL of iohexol,
OmnipaqueW 300, Daiichi Sankyo Co., Ltd.), fixed injection
duration (30 s), fixed scan timing at AP; Protocol-B,
BW-tailored dose of CM, fixed injection duration
(30 s), scan timing at AP adjusted by bolus tracking;
Protocol-C, BW-tailored dose of CM, fixed injection flow
rate, scan timing at AP adjusted by bolus tracking;Table 1 Subjects’ characteristics
Protocol-A Protocol-B
(n = 144) (n = 117)
Gender Male 111 (77.1) 79 (67.5)
Female 33 (22.9) 38 (32.5)
Age 73 ± 8.9 73 ± 8.9
BW 58.6 ± 12.0 57.4 ± 10.8
Note; Data presented as number (%) of patients or mean ± standard deviation (SD);Protocol-D, 100 mL constant of CM at any BW, fixed scan
timing at AP. Iodine dose per weight for BW-tailored dose
of CM in Protocols A, B and C, fixed scan start time at
AP in Protocols A and D, trigger and scan delay for AP by
bolus tracking in Protocols B and C, and fixed injection
flow rate in Protocol-C were decided as a clinical CT
examination in each hospital. In terms of the average, the
dose of CM per weight was higher in Protocols A and C,
and injection flow rate was highest in Protocol-A. Injec-
tion duration in Protocols C and D with fixed flow rate
was longer than 30 s, although the injection duration was
fixed as constant at 30 s in Protocols A and B (Table 3).
The delay time of AP from the initiation of CM injection
was recorded. In Protocol-B (mean ± SD / median, 34.92 ±
4.85 / 35.0 s) and C (32.77 ± 5.48 / 33.0 s) using bolus
tracking were earlier compared to those in Protocols A
(38.87 ± 2.95 / 40.0 s) and D (38.27 ± 4.19 / 40.0 s).
Our study data were obtained from 99 CT machines
(Toshiba 44, General Electric 32, Siemens 13, Philips 10)
in 91 hospitals. Fixed 5 mm slice thickness of CT images
was employed in all hospitals. And other CT imaging
parameters, such as detector-row, tube voltage and tube
current, are shown in Table 4. Liver dynamic CT images
were collected as electronic data (DICOM standard)




In order to ensure the reliability of reviewers, three inde-
pendent reviewers, who had more than 13 years of experi-
ence in liver CT, had a training of the judgment for the liver
dynamic CT to make criteria and consensus of qualitative
evaluation. After that, three reviewers evaluated all imaging
data in the points of scan timing of AP and the degree of
tumor conspicuity of HCC in the AP.
On the actual evaluation, the information on the
patient background, specific institutions and the imaging
techniques were blinded for reviewers. When reviewing
by three independent reviewers, the display setting of liver
dynamic CT images, such as window width (WW) and
window level (WL), was fixed as WW 270 and WL 60.
The efficacy of imaging in the diagnosis of HCC in the AP
of each liver segment was evaluated by the 3 independentProtocol-C Protocol-D Overall
(n = 87) (n = 67) (n = 415)
65 (74.7) 45 (67.2) 300 (72.3)
22 (25.3) 22 (32.8) 115 (27.7)
72 ± 8.6 71 ± 9.8 72 ± 9.0
59.0 ± 10.7 57.4 ± 11.6 58.1 ± 11.3
BW, body weight.
Table 2 Background, characteristics and diagnosis methods for hepatocellular carcinoma
Protocol-A Protocol-B Protocol-C Protocol-D
Background*
Hepatitis B 5 (3.5) 8 (6.8) 6 (6.9) 6 (9.0)
Hepatitis C 36 (25.0) 35 (29.9) 17 (19.5) 19 (28.4)
LC 104 (72.2) 75 (64.1) 65 (74.7) 42 (62.7)
LC-B 9 (6.3) 8 (6.8) 3 (3.4) 2 (3.0)
LC-C 75 (52.1) 51 (43.6) 45 (51.7) 28 (41.8)
LC-Alcoholic 13 (9.0) 9 (7.7) 11 (12.6) 13 (19.4)
NASH 5 (3.5) 1 (0.9) 0.(0.0) 0 (0.0)
Others 5 (3.5) 9 (7.7) 8 (9.2) 2 (3.0)
Fatty liver 1 (0.7) 0 (0.0) 3 (3.4) 2 (3.0)
Others 2 (1.4) 2 (1.7) 0 (0.0) 0 (0.0)
Characteristics
Size of tumor** (mm) 17.08 ± 6.42 16.85 ± 5.88 16.70 ± 6.27 16.60 ± 6.29
Range 3.0-30.0 5.6-30.0 7.0-30.0 6.6 − 29.0
<20 mm 89 (61.8) 73 (62.4) 62 (71.3) 45 (67.2)
>20 mm 55 (38.2) 44 (37.6) 25 (28.7) 22 (32.8)
Number of tumors 1-3 109 (75.7) 97 (82.9) 65 (74.7) 47 (70.1)
4-6 14 (9.7) 8 (6.8) 7 (8.0) 6 (9.0)
7-9 6 (4.2) 3 (2.6) 1 (1.1) 4 (6.0)
>10 15 (10.4) 9 (7.7) 14 (16.1) 10 (14.9)
Diagnosis methods*
Biopsy 5 (3.5) 1 (0.9) 0 (0.0) 0 (0.0)
CE-MRI 33 (22.9) 39 (33.3) 31 (35.6) 14 (20.9)
CTAP/CTHA 10 (6.9) 9 (7.7) 10 (11.5) 9 (13.4)
Angiography 29 (20.1) 43 (36.8) 10 (11.5) 26 (38.8)
Lipiodol CT 12 (8.3) 15 (12.8) 4 (4.6) 3 (4.5)
Sonography 42 (29.1) 56 (47.9) 40 (46.0) 28 (41.8)
Growth of tumor 45 (31.3) 27 (23.1) 37 (42.5) 11 (16.4)
Increased tumor markers 78 (54.2) 70 (59.8) 45 (51.7) 34 (50.7)
Note; Data presented as number (%) of patients or mean ± standard deviation (SD);
LC, Liver cirrhosis; NASH, non-alcoholic steatohepatitis, CE-MRI, Contrast-enhanced magnetic resonance imaging;
CTAP, computed tomography during arterial portography; CTHA, computed tomography during hepatic arteriography
** Background and diagnosis methods were made by multiple selections.
* Tumor selected as target tumor for quantitaive analysis.
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cuity: “excellent (HCC enhancement at AP ≥ the enhance-
ment of aorta)”, “good (liver parenchyma < < HCC
enhancement at AP < the enhancement of aorta)”, “fair
(liver parenchyma <HCC enhancement at AP < < the
enhancement of aorta)” and “poor (liver parenchyma ≥
HCC enhancement at AP)”. These gradings were employed
for the largest target 10 tumors. The scan timing of AP was
investigated by these 2 grades: “good (arterial and portal
vein enhancement of the liver are seen, but hepatic vein
enhancement is not seen)”, “poor (portal vein enhancement
is not seen, or both portal vein and hepatic vein inthe liver are seen)”. The evaluation result was adopted
when ratings given by 2 reviewers were consistent.
When ratings by 3 reviewers were completely incon-
sistent, the case was discussed to determine the final
rating.
Quantitative analysis
CT values (mean ± SD) in HU were measured and
recorded by physicians at each institution site as follows;
The mean attenuation of the abdominal aorta at the
level of main portal vein [region of interest (ROI) size,
approx. 1.0 cm2], hepatic parenchyma at the level of
Figure 1 Subjects’ body weight (BW) distribution. There was no significant difference in weight distribution between each group of four
protocols. -40; up to 40 kg of BW, 40 < −45; greater than 40 kg, up to 45 kg of BW, 45 < −50, 50 < −55, 55 < −60, 60 < −65, 65 < −70 and 70 < −80
are shown in similar to 40 < −45, 80<; greater than 80 kg of BW.
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section of right lobe and posterior section of right lobe of
the liver; each ROI size, approx. 2.0 cm2), and HCC (ROI
size, approx. 0.5 cm2) by using the CT attenuation values.
ROIs of liver parenchyma were placed not to cover liver
tumor region, visible blood vessel structure, bile ducts,
calcified areas and artifacts. The target HCC was selected
among the tumors within 3 cm in cases where there were
multiple regions. And HCC enhancement was evaluated in
the most enhanced portion of the tumor, when heteroge-
neous enhancement of HCC existed. The enhancement
effect at AP was calculated as the absolute difference in the
attenuation values of the abdominal aorta at unenhanced
scanning versus AP of contrast-enhanced scanning. When
automatic tube current modulation was used, data of SD
values exceeding twice the setting SD value were excluded.
Finally, the following parameters were calculated and used
for the analysis:
Aortic enhancement (HU) = density of aorta at AP
(HU) – density of aorta at unenhanced phase (HU)Table 3 Injection data of contrast material
Protocol-A
Total dose (mL) 113.9 ± 20.42
Dose per weight (mL/kg) 1.97 ± 0.275
Iodine dose per weight (mgI/kg) 589.6 ± 82.35
Injection flow rate (mL/sec) 3.79 ± 0.681
Injection duration (sec) 30.0
Note; Data presented as mean ± standard deviation (SD).The tumor conspicuity of HCC can be expressed by the
attenuation differences between HCC and surrounding
hepatic parenchyma - that is, tumor liver contrast (TLC).
TLC ¼ density of target tumor at AP HUð Þ
– density of hepatic parenchyma at AP HUð Þ
Scatter plot of the relationship between BW and TLC
at AP for each protocol was made to investigate the
degree of linear approximation.
Safety
Two of 419 patients were excluded because of the follow-
ing reason: one patient was not administered iohexol but
other iodine component that differ from the structured
study protocol, and one patient was found to have been
enrolled outside the contract period. Finally, the investiga-
tion into the safety of 300 mgI/mL of iohexol was
performed in remaining 417 patients. The adverseProtocol-B Protocol-C Protocol-D
109.3 ± 21.87 116.3 ± 19.89 100.0
1.90 ± 0.132 1.98 ± 0.138 1.81 ± 0.369
571.3 ± 39.61 593.9 ± 41.35 543.6 ± 110.7
3.64 ± 0.729 3.44 ± 0.334 3.21 ± 0.243
30.0 33.9 ± 5.51 31.3 ± 2.17
Table 4 Imaging methods for each computed tomography protocol
Protocol-A Protocol-B Protocol-C Protocol-D
Detector-rows 16 13 (33.3) 4 (12.9) 6 (40.0) 4 (28.6)
64 26 (66.7) 27 (87.1) 9 (60.0) 10 (71.4)
Tube voltage <120KV 1 (2.6) 0 (0.0) 0 (0.0) 0 (0.0)
120KV 36 (92.3) 29 (93.5) 15 (100.0) 14 (100.0)
>120KV 2 (5.1) 2 (6.5) 0 (0.0) 0 (0.0)
Tube current Auto 33 (84.6) 29 (93.5) 14 (93.3) 14 (100.0)
Fixed 6 (15.4) 2 (6.5) 1 (6.7) 0 (0.0)
Scan speed <0.5 4 (10.3) 2 (6.5) 1 (6.7) 0 (0.0)
0.5 20 (51.3) 26 (83.9) 12 (80.0) 11 (78.6)
0.5< 14 (35.9) 2 (6.5) 2 (13.3) 3 (21.4)
Unknown 1 (2.6) 1 (3.2) 0 (0.0) 0 (0.0)
Note; Data presented as number (%) of CT machines; KV, kilovolt.
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cians at each institution site.
Statistical analysis
For evaluation of the efficacy of imaging at AP, the best
rating given to segments obtained from each patient was
considered as the final rating for the patient. Moreover,
patients rated as “excellent” or “good” were defined as
those rated as “excellent or good”. The proportion of
patients who were rated as “excellent or good” in
each imaging protocol was compared by using a linear
probability model. To compare aortic enhancement and
quantitative TLC among the four imaging protocols, an
analysis of variance model was performed. Moreover, to
investigate the efficacy of 4 protocols in each BW range,
tumor conspicuity and quantitative TLC at AP were com-
pared according to the BW, which was divided into three
subgroups (< 50 kg vs. 50–60 kg vs. > 60 kg), and the rela-
tionship between BW and TLC at AP was shown with
scatter plots and the regression line by each protocol.
A P value less than 0.05 was considered to indicate
statistical significance and all analyzes were performed
by using SASW System Release 8.2 (SAS Institute Inc.,
Carey, NC, USA). Since this study was exploratory study,
sample size was determined without statistical consider-
ation and no adjustment for multiplicity was performed.
Results
Qualitative analysis
The qualitative rate assessed “good” as scan timing at
AP in Protocol-C was significantly lower than those
in Protocols A (difference: 16.6%, P = 0.0069) and D
(difference: 17.4%, P = 0.0140) (Figure 2). The qualita-
tive rates assessed “excellent or good” as tumor con-
spicuity at AP were Protocol-A, 81.3%, Protocol-B,
79.6%, Protocol-C, 80.7%, and Protocol-D, 76.9%. Inpatients with higher BW (> 60 kg), qualitative tumor
conspicuity at AP in Protocols A and B were higher than
those in Protocol-D (difference: 16.8%, P = 0.1509, 21.1%,
P = 0.0669, respectively), and the highest tumor con-
spicuity was obtained in Protocol-B, which was fixed
duration with bolus tracking (Figure 3). Whereas, in
the subgroup of BW ≤ 50 kg, tumor conspicuity in
Protocol-B showed the lowest value of the 4 protocols.
Quantitative analysis
In the subgroup of BW > 60 kg, the aortic enhancement
was significantly lower in Protocol-D (the amount of
iodine especially in Protocol-D was less than in the other
groups). Subgroups of 50 kg < BW ≤ 60 kg and BW ≤
50 kg did not show significant differences in the aortic
enhancement between the 4 protocols (Figure 4). The
TLC of HCC obtained in the subgroup of BW > 60 kg
was not discrepant with the quantitative evaluation of
the aorta enhancement (Figure 5). And quantitative TLC
at AP in Protocols A, B, C was lower than that in patients
with lower BW (≤ 50 kg) in Protocol-D. In particular,
TLC in Protocol-B was significantly lower than that
in Protocol-D (difference: 17.00HU, P = 0.0249).
Scatter plot of the relationship between BW and
TLC at AP was shown in Figure 6. R2 of Protocol-D
(0.1283) was closer to 1 than those of Protocols A, B, C
(Protocol-A; 0.0003, Protocol-B; 0.0008, and Protocol-C;
0.0454), and Protocol-D showed significant inverse
relationship between BW and TLC (P = 0.0053).
Safety
The CM was well tolerated by the patients. There were no
clinically relevant changes in hemodynamic or laboratory
parameters. No death or any adverse event leading to the
discontinuation of a patient’s participation in the study
was reported. Of the 417 patients who were investigated
Figure 2 Qualitative rate assessed “good” as scan timing at arterial phase (AP). The qualitative rate assessed “good” as scan timing at AP in
Protocol-C was significantly lower than those in Protocol-A (*; P = 0.0069) and D (**; P = 0.0140 ). Error bars indicate 95% confidence interval.
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reported adverse reactions, including sneezing in 1 patient
(0.69%, 1/144) in Protocol-A, drug eruption in 1 patient
and urticaria in 1 patient (1.70%, 2/118) in Protocol-B,Figure 3 The rate of patients rated as “excellent or good” in the qual
qualitative evaluation, tumor conspicuity of hepatocellular carcinoma obtai
with the quantitative evaluation of the aorta enhancement (Figure 4). In th
be lower than those in the other groups, and the highest tumor conspicui
bolus tracking. In the subgroups of BW ≤ 50 kg, tumor conspicuity in Proto
indicate 95% confidence interval. -50; up to 50 kg of BW, 50 < −60; greatereczema in 1 patient and nausea in 1 patient (2.30%, 2/87)
in Protocol-C, and nausea in 1 patient (1.47%, 1/68) in
Protocol-D. Both patients who had nausea recovered
without treatment, and the rest of 4 patients (0.96%) wereitative tumor conspicuity at arterial phase (AP). Regarding
ned in the subgroup of body weight (BW) > 60 kg was not discrepant
e subgroup of BW > 60 kg, tumor conspicuity in Protocol-D tended to
ty was obtained in Protocol-B, which included fixed duration with
col-B tended to be lower than those in the other groups. Error bars
than 50 kg, up to 60 kg of BW, 60<; greater than 60 kg of BW.
Figure 4 Quantitative aortic enhancement at arterial phase (AP). The timing of AP in Protocols B and C was early, so that contrast
enhancement of the aorta was better than with the other protocols. It is suitable for the contrast imaging of the aorta in Protocols B and C. In the
subgroup of body weight (BW) > 60 kg, the amount of iodine especially in Protocol-D was less than those in the other groups, and the aortic
enhancement was significantly lower in Protocol-D by analysis of variance. (*; P < 0.001, **; P < 0.001, *** P = 0.0011). In the subgroups of BW≤ 50 kg,
the aortic enhancement in Protocol-C tended to be higher than those in the other groups. Error bars indicate 95% confidence interval. CT; computed
tomography, HU; Hounsfield unit. -50; up to 50 kg of BW, 50 < −60; greater than 50 kg, up to 60 kg of BW, 60<; greater than 60 kg of BW.
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steroid, antihistamine, glycyrrhizin for treatment of
adverse reactions. A total of 3 (0.72%) patients reported
extravasation; 1 patient (0.69%, 1/144) on Protocol-A, 1
(0.85%, 1/118) on Protocol-B, and 1 (1.15%, 1/87) on
Protocol-C. But, there was no significant difference in
the incidence and the trend of adverse reactions and
extravasations among the 4 protocols. Moreover, we
did not identify any concerns about safety in the
constant injection duration method, although the infusion
rate in patients with high BW would be increased by
setting injection duration as constant.
Discussion
Our study showed that in patients with higher BW
(> 50 kg), protocols of BW-tailored dose of CM and/or
fixed injection duration had higher tumor conspicuity to
diagnose hypervascular HCCs, because they had higher
tumor conspicuity and TLC of HCC than a fixed dose
(100 mL) of CM. Whereas, the use of a CM with a con-
centration of 300 mgI/mL with fixed 100 mL was higher
tumor conspicuity and TLC of HCC for dynamic hepatic
CT in patients of BW ≤ 50 kg, since the volume of
CM was injected in overload for those patients. To
our knowledge, this study is the first prospectivestudy evaluated the role of CM injection protocols for
a large number of patients in community hospitals,
although these results are theoretically presumable.
In 4 protocols of our study, we disclosed the relation-
ship of BW and TLC at AP. R2 (0.1283) in Protocol-D
showed closer linear approximation between BW and
TLC, although the R2 was not high. This means that
Protocol-D may not achieve diagnostically sufficient
TLC in patients with higher BW. Protocol-D is not
recommended for a liver CT, because injection protocol
should be stable for all patients with wide range of BW.
Many patients are diagnosed in community hospitals.
The optimal injection method on liver CT is required to
detect HCC in not only academic organizations, but also
community hospitals. From our results, we can call
attention to staffs in the department of radiology
worldwide including community hospitals in regard to
the optimal injection protocol for HCC. We believe
that liver dynamic CT protocols with BW-tailored
dose of CM, fixed injection duration and scan timing at
AP decided by bolus tracking should be recommended to
obtain optimal HCC enhancement, because fixed injection
duration can minimize the patients’ variables and can
make the scan timing for each phase more uniform
among all patients (Awai et al. 2004b; Bae 2003). However,
Figure 5 Quantitative tumor liver contrast (TLC) at arterial phase (AP). Regarding quantitative evaluation, the subgroup of body weight
(BW)≤ 50 kg in Protocol-D showed a significantly higher TLC of hepatocellular carcinoma compared with Protocol-B by analysis of variance.
(*; P= 0.0249, because it is considered that an excessive amount of iodine was administered to patients with low BW in Protocol-D). In the subgroup of
BW> 60 kg, the TLC in Protocol-D was less than those in the other groups. Error bars indicate 95% confidence interval. CT; computed tomography, HU;
Hounsfield unit. -50; up to 50 kg of BW, 50 < −60; greater than 50 kg, up to 60 kg of BW, 60<; greater than 60 kg of BW.
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chronic liver diseases should be investigated to detect
hypervascular HCC in the future. And scan delay at
AP by bolus tracking should be more optimized in
each hospital.
Awai et al. reported that 520 mgI/kg of contrast dose was
not enough for liver enhancement in patients with chronic
liver damage (Awai et al. 2004a), and Yamashita et al.
reported that 600 mgI/kg of contrast dose is recommended
for liver enhancement in patients with chronic liver damage
(Yamashita et al. 2000). The mean contrast dose in our
study was 543.6 to 593.9 mgI/kg (Table 3) in the 4 proto-
cols. Thus, we believe that almost all cases had enough con-
trast dose in our study, except in patients with Protocol-D
(mean contrast dose; 543.6 mgI/kg).
Injection rate is an important factor to detect
hypervascularity of HCC at AP. Higher injection rate of
CM allows higher HCC enhancement at AP, and TLC of
HCC increases (Yanaga et al. 2007). In our study, mean
of the injection flow rate in Protocol-A (3.79 mL/sec)
was higher than other protocols (Table 3). In general,
the higher injection flow rate works better to obtain
higher detection rate of HCC, when other injection
parameters are constant (Kim et al. 1995). A reason why
Protocol-A did not achieve highest tumor conspicuity
and TLC among the 4 protocols is that injection rate isonly one factor for tumor conspicuity and TLC of HCC,
and various other factors such as iodine dose, scan timing
for AP relates to tumor conspicuity and TLC. In our study,
injection duration, injected dose of CM per BW and scan
timing at AP were different between 4 protocols. Thus the
higher injection flow rate may be one reason that increases
tumor conspicuity and TLC of HCC, although Protocol-A
did not show higher tumor conspicuity and TLC than
other protocols (Figures 3 and 5).
Kim et al. stated that an injection rate of 3 – 5 ml/sec
took a mean 18 or 19 s to reach the threshold of 100 HU
in the aorta (Kim et al. 1998). Sultana et al. reported an
18 s delay from bolus tracking to depict hypervascular
HCC in the setting of trigger threshold level 100 HU in
the aorta with an injection duration of 25 s by using
40 detectors-row CT (Sultana et al. 2007). Therefore,
the optimal scan delay at AP from the initiation of CM
injection is calculated as follows;
Scan delay at AP ¼ 18 s or 19 sð Þ þ 18 s
¼ 36 s or 37 sð Þ
This formula is applied in the case of a 25 s injection
duration, thus the next formula is applied in the case of
a 30 s injection duration
Figure 6 Scatter plot of the relationship between body weight (BW; kg) and tumor liver contrast (TLC) at arterial phase (AP). Protocol-D
showed closer linear approximation between BW and TLC between 4 protocols, because R2 of Protocol-D was closer to 1 than those of Protocols
A, B, C. Protocol-D showed significant inverse relationship between BW and TLC (P = 0.0053). HU; Hounsfield unit.
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Moreover, when the injection duration is fixed, the
peak enhancement times of aorta, portal vein, and
liver constantly are approximately 10 s, 20 s, and 30 s
after the any fixed injection durations, respectively
(Ichikawa et al. 2006; Erturk et al. 2008). And the use of
fixed injection duration (30 s) and scan delay of AP
(approximately 40 s; 30 s + 10 s) after the start of CM injec-
tion are recommended to obtain sufficient peak enhance-
ment value of hypervascular HCC (Ichikawa et al. 2006).
As shown in the result of our study, median of the delay
time in Protocols A and D at the AP was 40.0 s after the
start of CM injection. This fact was based on the theory of
“CM injection duration time + 10 s” for the AP on
liver dynamic CT.
In Protocols B and C with bolus tracking system, the
mean scan delay at AP was 34.92 s for Protocol-B and32.77 s for Protocol-C, therefore they were early for the
AP to depict hypervascular HCC. We thought that this
is a valuable findings only through the Post-marketing sur-
veillance by collecting data from the situation in the daily
clinical settings in the community hospitals. This may be
one of the causes of lower TLC in Protocols B and C than
in Protocol-D in the subgroup of BW ≤ 50 kg (Figure 6).
In addition, another cause is hypothesized that Protocol-D
had superfluous iodine dose in regard to patients’ BW in
the subgroup of BW ≤ 50 kg.
We believe that the scan delay for the AP in Protocols
B and C used in daily clinical settings in the community
hospitals was shorter than optimal. This may result in
the lower tumor conspicuity and TLC in the qualitative
and quantitative analysis. Therefore the trigger point of
CM arrival and the scan delayed time after aortic arrival
by using bolus tracking system should be optimized.
There are several potential limitations of our study
design. First, our study includes heterogeneous protocols
for dynamic liver CT, and characters of HCC are different
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large number of patients to overcome the variations
among patients. Second, a bolus tracking system may not
work as optimized scan delay in several hospitals, because
the delay after bolus tracking for AP is shorter than
other protocols without bolus tracking systems. From
our results, we should warn diagnostic radiologists
that liver dynamic CT has to be performed with an
optimal time delay after the threshold of the bolus
tracking system. Third, our fixed dose (100 mL) of
300 mgI/mL of iohexol appears to be inadequate for
Western people. However, most of the patients in our
study weighed less than 60 kg (mean, 58.1 kg), and
100 mL is still used in Japanese hospitals, so we
chose this dose for Protocol-D. Our results should be
more obvious in a Western population with a higher
mean body weight of 70 kg or more. Despite these
limitations, we believe it clinically significant that the
finding on the protocols of BW-tailored dose of CM
and/or fixed injection duration indicated by the data
obtained from single institution was replicated also in daily
clinical settings, especially to standardize CM injection
protocol nationwide or worldwide.
In patients with higher BW (> 60 kg), protocols of
BW-tailored dose of CM and/or fixed injection duration
should be employed to diagnose hypervascular HCCs.
Use of CM with constant 100 mL at any BW and
fixed scan timing is not recommended for dynamic
hepatic CT, except in patients with lower BW (≤ 50 kg).
Moreover, when using bolus tracking system, its settings
such as the trigger point and the scan delayed time should
be optimized.
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